Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Aug 18, 2024 4:23pm
279 Views
Post# 36185122

weekend update & week ahead

weekend update & week ahead Hello all
As I mentioned previously, I have a lot going on right now.
Saying thst, I bought a few more Onc shares last week.
updste?
Nothing new for those in the know.
The pancreatic cancer phase 3 / registration trial still expects to start up , early 2025.
The very very long awaited O.S. Results for the MBc phase 2 bracelet trial, due reportedly before end if this year.
Presently the do not have a named partner/ colaborators for the next steps with MBc.
They did indicate positive results will increase their negotiation strength. While that is an obvious statement, worth stating.
Considering it is a near copy if the previous phase 2 trial & indications of strong results, almost an assumed conclusion.
Add- on since then, they had a meeting with FDA to further refine the process, including accepting biomarkers & other details....the strength going into phase 3 should be a very positive trinket for a potential partner.
They also started enrolment into an additional arm , for the Gobblet trial with Roche.
Where 2 yrs ago, Onc was a one phase 3 potential, now 2 , with a possible 3rd.
The SP refects none of those realities, therfore imho way beyond silly.
Could everything fall flat? Possible. Not likeky.
CGAR the lead colaborator with panc cancer & preceeeded by PanCan , precision promise detailed D.D. , donated $5million...and are in full support of the upcoming panc cancer opportunity.
Everyone, have a great week.



<< Previous
Bullboard Posts
Next >>